Overview
Adrenocortical carcinoma (ACC) is a rare and heterogeneous malignancy with poor prognosis. Surgical resection of the tumor is the treatment of choice. However, even after complete resection more than 80 % of patients will experience recurrence of disease. Therefore, new treatment options are urgently needed. This pre-clinical study try to lay the foundations for a successful immunotherapy in patients with ACC.
Eligibility
Inclusion Criteria:
- patients with histological proven adrenocortical carcinoma
- healthy persons as control group
- Life expectancy > 6 months
Exclusion Criteria:
- autoimmune diseases
- severe clinical condition
